Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed
20,000-participant BLUE-C study included.
The new test detected 94% of cancers and was 91% accurate in determining who didn’t have cancer, up from 92% cancer sensitivity and 87% specificity for the original Cologuard.
Exact Sciences: Launches Riskguard wisbusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wisbusiness.com Daily Mail and Mail on Sunday newspapers.
28.02.2024 - Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard hereditary cancer test in the United States. The Riskguard test provides an individualized patient report that includes . Seite 1